Inovio Pharmaceuticals, Inc. $INO Shares Sold by Two Seas Capital LP

Two Seas Capital LP lessened its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 26.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,479,493 shares of the biopharmaceutical company’s stock after selling 1,267,017 shares during the quarter. Inovio Pharmaceuticals makes up 2.8% of Two Seas Capital LP’s investment portfolio, making the stock its 6th largest holding. Two Seas Capital LP’s holdings in Inovio Pharmaceuticals were worth $142,764,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Eversept Partners LP purchased a new position in Inovio Pharmaceuticals during the 1st quarter valued at about $1,802,000. GSA Capital Partners LLP grew its position in Inovio Pharmaceuticals by 3.8% in the 4th quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 16,724 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Inovio Pharmaceuticals during the third quarter worth about $41,000. Raymond James Financial Inc. increased its stake in Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 16,309 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its stake in Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.18 on Friday. The stock’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.29. Inovio Pharmaceuticals, Inc. has a 1-year low of $0.56 and a 1-year high of $2.98. The company has a market cap of $122.01 million, a price-to-earnings ratio of -1.30 and a beta of 1.52.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.15. Equities research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on INO shares. Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Thursday, August 13th. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and upped their target price for the stock from $1.80 to $3.00 in a research note on Thursday, August 13th. Zacks Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 12th. Finally, Piper Sandler restated an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Inovio Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $3.17.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.